Bioequivalence and Bioavailability Forum 14:21 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Ramesh Ramalingam
Junior

India,
2018-10-18 07:16

Posting: # 19463
Views: 230
 

 Theophylline ER 450 mg study design [Design Issues]

Dear Members,

Based on literature reference, Theophylline is a narrow therapeutic index drug. As per USFDA recommendation if the drugs falls under narrow therapeutic index, the BE study should be a fully replicated crossover design in order to:
• Scale bioequivalence limits to the variability of the reference product; and
• Compare test and reference products within-subject variability.

But respective molecule OGD (which was issued on 2010) Draft guidelines recommending two-way cross-over study design.

Could you please suggest the study design whether it should be two-period, two-way crossover design or four period, fully replicated design.


Regards,
Ramesh
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,883 posts in 4,027 threads, 1,271 registered users;
online 33 (0 registered, 33 guests [including 33 identified bots]).

Those who make no mistakes are making the biggest mistakes of all –
they are attempting nothing new.    Anthony de Mello

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed